Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Medicxi Ventures

Founders David Grainger Francesco Rubertis Giuseppe Zocco Kevin Johnson Michele Ollier

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 45
Average round size
info
The average size of a deal this fund participated in
$43M
Portfolio companies 36
Rounds per year 5.62
Lead investments 20
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 4
Key employees 11

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Therapeutics
  • Health Care
  • Medical
Summary

In 2016 was created Medicxi Ventures, which is appeared as VC. The fund was located in Europe if to be more exact in United Kingdom. The leading representative office of defined VC is situated in the London.

Among the various public portfolio startups of the fund, we may underline SutroVax, Diasome, Aura Biosciences Among the most successful fund investment fields, there are Biopharma, Genetics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low.

The fund was created by David Grainger, Francesco Rubertis, Giuseppe Zocco, Kevin Johnson, Michele Ollier. The overall number of key employees were 11.

The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 54 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2018. The fund is constantly included in 2-6 investment rounds annually. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Medicxi Ventures works on 20 percentage points less the average amount of lead investments.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Medicxi Ventures, startups are often financed by Ysios Capital, Roche Venture Fund, Longitude Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, University of Cambridge Enterprise, OUP (Osage University Partners). In the next rounds fund is usually obtained by Silicon Valley Bank, Oberland Capital, Kite Pharma.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Medicxi Ventures:
Typical Co-investors
Medicxi Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Medicxi Ventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Angel Healthcare Investors Massachusetts, Newton, United States
Ascendas-Singbridge Central, Central Region, Singapore
Baylis Medical Company Canada, Montréal, Quebec
BioCrossroads Indiana, Indianapolis, United States
Candela Partners California, San Francisco, United States
Exium Partners Fairport, New York, United States
Just Business California, San Francisco, United States
Liberty Technologies, Inc. Liberty, Missouri, United States
Meiwei Buyongdeng China, Shanghai
New Era Ventures District of Columbia, United States, Washington
Nifco England, Stockton-on-Tees, United Kingdom
Pacific West Bank Oregon, United States, West Linn
Palm Beach Capital Florida, United States, West Palm Beach
PaRan GongCheng Beijing, Beijing, China
Shilan Zichan Guanli -
Sigma Capital Group City of Edinburgh, Scotland, United Kingdom
Stratel Norway, Oslo
Velvet Sea Ventures Delaware, Dover, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ProfoundBio

Biotechnology
Therapeutics
$112M13 Feb 2024 Suzhou, Jiangsu, China

Alys Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$100M12 Feb 2024 Boston, Massachusetts, United States

Aldena Therapeutics

Biotechnology
Therapeutics
$30M16 Mar 2023 Boston, Massachusetts, United States

Rivus Pharmaceuticals

Biotechnology
Health Care
Medical
Pharmaceutical
$132M22 Sep 2022 Charlottesville, Virginia, United States

MiroBio

Biotechnology
Life Science
$109M29 Jun 2022 Oxford, England, United Kingdom

Versanis Bio

Biotechnology
Life Science
Medical
Pharmaceutical
$70M31 Aug 2021 Oakland, California, United States

Sydnexis

Manufacturing
Pharmaceutical
$45M10 Aug 2021 California, United States

Rivus Pharmaceuticals

Biotechnology
Health Care
Medical
Pharmaceutical
$35M20 Jul 2021 Charlottesville, Virginia, United States

Kurome Therapeutics

Biotechnology
Health Care
Therapeutics
$15M10 Jun 2021 Cincinnati, Ohio, United States
News
Versanis Bio Raises $70M in Series A Financing

– Versanis Bio is an Oakland, Calif.-based company established to discover and develop first-in-class medicines that address medical conditions prevalent in older adults.
– The company closed a $70m Series A financing.
– The round was co-led by Atlas Venture and Medicxi with participation from Aditum Bio.
– The company intends to use the funds to advance a comprehensive phase 2 clinical program to evaluate the potential of bimagrumab to help obese patients lose fat and achieve an improved body composition.

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

– Sydnexis, Inc. completed a $45m Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.
– The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.
– Sydnexis’ STAAR study is the largest pediatric myopia study globally to investigate the use of low dose atropine to retard progressive myopia. In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Medicxi Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 45
Average round size 43M
Rounds per year 5.62
Peak activity year 2017
Lead investments 20
Follow on index 0.20
Exits 4
Group Appearance index 0.67

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

ProfoundBio

Biotechnology
Therapeutics
$112M13 Feb 2024 Suzhou, Jiangsu, China

Alys Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$100M12 Feb 2024 Boston, Massachusetts, United States

Aldena Therapeutics

Biotechnology
Therapeutics
$30M16 Mar 2023 Boston, Massachusetts, United States

Rivus Pharmaceuticals

Biotechnology
Health Care
Medical
Pharmaceutical
$132M22 Sep 2022 Charlottesville, Virginia, United States

MiroBio

Biotechnology
Life Science
$109M29 Jun 2022 Oxford, England, United Kingdom

Versanis Bio

Biotechnology
Life Science
Medical
Pharmaceutical
$70M31 Aug 2021 Oakland, California, United States

Sydnexis

Manufacturing
Pharmaceutical
$45M10 Aug 2021 California, United States

Rivus Pharmaceuticals

Biotechnology
Health Care
Medical
Pharmaceutical
$35M20 Jul 2021 Charlottesville, Virginia, United States

Kurome Therapeutics

Biotechnology
Health Care
Therapeutics
$15M10 Jun 2021 Cincinnati, Ohio, United States
Crunchbase icon

Content report

The following text will be sent to our editors: